Members of the transient receptor potential (TRP) superfamily of ion channels are leading candidates for mediating compartmentalized Ca 2ϩ release. 1 TRP channels are best known for their diverse physiologic role as cellular sensors contributing to thermal, tactile, taste, and osmolar and fluid flow sensing and mechanosensation. The discovery of the TRP family member TRPC6 in podocyte foot processes as part of the slit diaphragm protein complex 2 suggests that podocyte foot processes are functional Ca 2ϩ compartments. This opens the question about the role of Ca 2ϩ signaling in foot processes for normal podocyte structure and function and thereby for the maintenance of a proper glomerular filtration barrier.
The integral role for TRPC6 in kidney podocytes is underscored by the observation that mutations of TRPC6 are associated with FSGS. 2, 3 Six disease-causing mutations in the human TRPC6 gene have been identified to date, three of which appear as gain-of-function mutations of TRPC6 ion channels, allowing the influx of more Ca 2ϩ into cells than their tightly regulated wild-type counterparts, the others staying longer open, once activated (our own unpublished data). 2, 3 Furthermore, in several acquired human and experimental proteinuric kidney diseases, wild-type TRPC6 is induced in glomeruli at both the mRNA and protein levels. 4 These findings suggest high abundance of wild-type TRPC6 channels in podocytes contribute to a similar pathophysiology as the presence of mutated, overly active channels. Two major questions remain: What regulates TRPC6 channels in podocytes, and what effects does TRPC6-mediated Ca 2ϩ influx elicit in this cell?
Useful hints for TRPC6 function in podocytes derive from the known roles of TRPC channels in other cell types sharing typical features with podocytes, including smooth muscle cells and neurons. Besides that, we might be able to draw important conclusions from what is known about the role of the glomerular slit diaphragm and the typical phenotypic changes that podocytes undergo during acute injury or chronic damage.
IMPLICATIONS OF THE INTERACTION OF TRPC6 WITH THE SLIT DIAPHRAGM
TRPC6 interacts with two proteins that are key effectors between podocytes: Podocin and nephrin. 2 The interaction of TRPC6 with the stomatin family member podocin, whose homologue mec-2 is a contributor to mechanosensation in the worm Caenorhabditis elegans, places TRPC6 at the site of a putative mechanosensor complex at the slit diaphragm ( Figure 1 ). Being subject to mechanical force in a vertical direction from fluid flow across the membrane and in a lateral direction from contact between neighboring podocytes, such a complex could participate in monitoring glomerular pressure, or filtration rate, and help podocytes adapt to changes in the microenvironment of the glomerular filtration barrier. A report by Huber et al. 5 substantiated this notion by demonstrating that podocin in heterologous expression systems regulates the activity of TRPC6 in a cholesterol-dependent manner.
In fact, several TRP channels have the capability to sense mechanical stretch directly; that is, conformational changes induced by stretch of the plasma membrane are sufficient to render the channel pore permeable. Spassova et al. 6 showed that TRPC6 responds to pressure stimuli even in the presence of phospholipase C blockers, arguing against second-messenger activation and in favor of direct activation through membrane stretch. The authors of that study suggested a common molecular basis for lipid-mediated membrane stretch activation and the widely known activation of TRPC6 through diacylglycerol. 1 In both cases, the mechanism underlying channel activation is a conformational change rendering TRPC6 channels permeable.
The concept of a mechanosensor at the slit diaphragm would be well in line with findings derived from human genetics; as is the case for TRPC6, it is widely known that mutations in the NPHS2 gene encoding podocin cause hereditary nephrotic syndrome in humans. Although TRPC6-associated disease displays a later onset of kidney failure and milder symptoms than the podocin disease, the similarity of the defects supports the concept that podocin modulates TRPC6 function. Also is the notion that TRPC6 function is partly compensated by other TRPC proteins, but there is no known podocin analogue that could explain the more severe phenotype for NPHS2 mutations as compared with TRPC6 mutations.
It is further suggested that the slit diaphragm serves not only as a molecular sieve but also-similar to other cell-cell junctions-as a platform mediating signals required for sustained podocyte structure and function. 7 The slit diaphragm protein, nephrin, contributes to actin reorganization in podocytes through a phosphoinositide 3-kinase pathway. 8 In addition, tyrosine phosphorylation, which is a key event in signal transduction, occurs at the slit diaphragm site: The Src family protein tyrosine kinase Fyn binds and phosphorylates nephrin. 9 Upon phosphorylation by Fyn, nephrin can bind Nck adapter proteins, an event that in turn reorganizes the actin cytoskeleton. 9 Interestingly, TRPC6 is also a target of phosphorylation by Fyn, enhancing TRPC6 channel activity. 10 Together, these findings suggest TRPC6 is assembled in a complex together with nephrin and Fyn at the slit diaphragm, and this complex is partly regulated by tyrosine phosphorylation of nephrin and/or TRPC6.
TRPC6 as a component of a podocin-TRPC6-mechanosensor complex and/or nephrin-Fyn-TRPC6 signaling complex could be involved in monitoring the integrity of the slit diaphragm, which relates Ca 2ϩ -signaling cascades into the foot process that are required to induce adaptive changes in the dynamic, contractile podocyte actin cytoskeleton. 11 Under disease conditions, alteration of TRPC6 function directly affect the cytoskeletal response of podocytes and therefore play a major role during podocyte injury and foot process effacement (Figure 2) .
Given that Ca 2ϩ responses can be subdivided into short-term, rapid responses that do not involve transcriptional changes and long-term modifications that require changes in gene The space between neighboring foot processes is filled by the glomerular slit diaphragm, a zipper-like structure formed by a number of podocyte proteins, including nephrin, neph1-3, pcadherin, and FAT. Other podocyte proteins are located in close vicinity of the slit diaphragm, such as the stomatin family member podocin and the ion channel TRPC6. Adapter proteins including CD2AP and Nck connect the slit diaphragm to the podocyte actin cytoskeleton. The podocyte actin-based cytoskeleton includes thick bundles of actin running inside foot processes and cortical actin decorating the inner surface of foot processes. ␣-Actinin-4 and synaptopodin are critical cross-linkers of podocyte actin, and the large GTPase dynamin functions as a vital regulator of the podocyte actin cytoskeleton. The sialoglycoprotein podocalyxin is located at the podocyte apical surface and is thought to be the major constituent of the podocyte glycocalyx. Signaling via the urokinase receptor (uPAR) in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of ␣v␤3-integrin.
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www.jasn.org transcription, it is also possible that TRPC6 acts as a modulator of podocyte transcriptional machinery. Along these lines, Kuwahara et al. 12 found that TRPC6 is a key component of a Ca 2ϩ -dependent regulatory loop that drives pathologic cardiac remodeling through the calcineurin-NFAT pathway. Given that one of the most widely used drugs in the treatment of idiopathic glomerular kidney disease are inhibitors of calcineurin, it will be very interesting to determine whether a similar pathway has physiologic relevance in podocytes and, if this is the case, to identify target genes of TRPC6-mediated transcriptional regulation.
ARE TRPC6 ؊/؊ MICE A SUITABLE MODEL FOR TRPC6-RELATED HUMAN DISEASE?
For studying the pathogenic mechanisms behind many inherited human diseases, important insights can be drawn from the study of genetic animal models. TRPC6-deficient mice have been characterized. 13 Young TRPC6 Ϫ/Ϫ mice lack an overt renal phenotype; however, thus far, no study has explicitly addressed the renal phenotype in TRPC6-deficient mice that are stressed. Moreover, given the late onset of the TRPC6-related human disease, aged deficient mice would have to be studied. Finally, the role of TRPC6 in the kidney may be different in human and mouse, and the findings in the animal model may simply not be directly applicable to the human disease phenotype. The latter notion is supported by our own studies in zebrafish, in which TRPC6 was absent in developing and adult podocytes. 14 An explanation for the lack of an overt phenotype of TRPC6 Ϫ/Ϫ mice is provided by the second-hit hypothesis. In the context of mutations in the ACTN4 gene encoding the actin bundling protein (similar to mutations in TRPC6), ␣-actinin-4 results in late-onset FSGS in various degrees of severity. It has been suggested that, besides the sole presence of mutations, second physiologic hits such as variations in glomerular capillary pressure (e.g., caused by hypertension) or metabolic disturbance (e.g., caused by diabetes) may be required for the clinical manifestation of disease. Another possible disease modifier upstream of TRPC6 activity is the absence or presence of serum factors; for example, a yet-to-beidentified FSGS factor modulating TRPC6 stimulation. A second-hit hypothesis could explain the absence of a disease phenotype in TRPC6 Ϫ/Ϫ mice. The presence of second hits in different degrees could also explain why some individuals present with clinical symptoms much earlier than others with the same mutation. Furthermore, recent findings in bigenic mouse models of glomerular disease illustrate that mutations in genes other than TRPC6 may have to be taken into account when exploring the pathophysiology of TRPC6-related disease. 15 For advancing our understanding of the role of TRPC6, the development of tissue-specific transgenic mice will be of great help. Podocyte-specific gene targeting became possible with cloning of podocyte-specific promoters. 16 It will be very interesting to see whether podocytespecific TRPC6 Ϫ/Ϫ mice, or mice overexpressing TRPC6 in a podocyte-specific manner, have a renal phenotype or respond differently to experimental challenge. Importantly, these animal models will also help us to distinguish between the pathophysiologic roles of TRPC6 in podocytes and in other cell types in the nephron, including glomerular endothelial and tubular epithelial cells.
CONCLUSIONS
The discovery of TRPC6 as part of the slit diaphragm in podocytes opens a new field for glomerular research, which is potentially amenable to therapy. (Figure 1 ).
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